JP2012067115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012067115A5 JP2012067115A5 JP2011243450A JP2011243450A JP2012067115A5 JP 2012067115 A5 JP2012067115 A5 JP 2012067115A5 JP 2011243450 A JP2011243450 A JP 2011243450A JP 2011243450 A JP2011243450 A JP 2011243450A JP 2012067115 A5 JP2012067115 A5 JP 2012067115A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- blend
- rate controlling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 32
- 239000006186 oral dosage form Substances 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 9
- 238000010521 absorption reaction Methods 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 229940122361 Bisphosphonate Drugs 0.000 claims 7
- 150000004663 bisphosphonates Chemical class 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- -1 medium chain fatty acid salt Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003605 opacifier Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229960005480 sodium caprylate Drugs 0.000 claims 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 1
- 229940082004 sodium laurate Drugs 0.000 claims 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12104899P | 1999-02-22 | 1999-02-22 | |
| US60/121,048 | 1999-02-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000600624A Division JP2002537321A (ja) | 1999-02-22 | 2000-02-22 | 促進剤を含む固体経口剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012067115A JP2012067115A (ja) | 2012-04-05 |
| JP2012067115A5 true JP2012067115A5 (enExample) | 2012-09-20 |
| JP5412491B2 JP5412491B2 (ja) | 2014-02-12 |
Family
ID=22394170
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000600624A Pending JP2002537321A (ja) | 1999-02-22 | 2000-02-22 | 促進剤を含む固体経口剤形 |
| JP2011243450A Expired - Fee Related JP5412491B2 (ja) | 1999-02-22 | 2011-11-07 | 促進剤を含む固体経口剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000600624A Pending JP2002537321A (ja) | 1999-02-22 | 2000-02-22 | 促進剤を含む固体経口剤形 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1154761B1 (enExample) |
| JP (2) | JP2002537321A (enExample) |
| AT (1) | ATE386508T1 (enExample) |
| AU (1) | AU2681300A (enExample) |
| CA (1) | CA2363123C (enExample) |
| DE (1) | DE60038097T2 (enExample) |
| ES (1) | ES2301477T3 (enExample) |
| WO (1) | WO2000050012A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1128858A1 (en) | 1998-11-13 | 2001-09-05 | Elan Pharma International Limited | Drug delivery systems and methods |
| US7084279B1 (en) | 1999-02-11 | 2006-08-01 | Emisphere Technologies Inc. | Oxadiazole compounds and compositions for delivering active agents |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| JP2007016034A (ja) * | 2000-12-26 | 2007-01-25 | Kirin Brewery Co Ltd | 吸収促進剤 |
| KR20040018333A (ko) * | 2001-02-16 | 2004-03-03 | 시미즈 세이야꾸 가부시키가이샤 | 소장 전달용 점액다당류 함유 경구 제형, 및 순환 장애치료에서의 이들의 용도 |
| WO2002092616A1 (en) | 2001-05-11 | 2002-11-21 | Orasense, Ltd. | Antisense permeation enhancers |
| US20050232981A1 (en) | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| AU2014200247B2 (en) * | 2004-07-19 | 2015-05-14 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| WO2006014673A2 (en) * | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP4759289B2 (ja) * | 2005-03-02 | 2011-08-31 | 国立大学法人北海道大学 | カルシウム吸収促進組成物およびその利用 |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| EP2040731A4 (en) * | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| AR062721A1 (es) * | 2006-09-12 | 2008-11-26 | Glaxo Group Ltd | Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla |
| KR101234540B1 (ko) * | 2007-10-16 | 2013-02-19 | 바이오콘 리미티드 | 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법 |
| CA2704778C (en) * | 2007-11-05 | 2014-04-29 | Scolr Pharma, Inc. | Formulations for enhanced bioavailability of orally administered polar agents |
| US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| GB0904942D0 (en) * | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| WO2011084618A2 (en) | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| CA2819108A1 (en) * | 2010-12-15 | 2012-06-21 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
| CA2832811A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| HUE064694T2 (hu) | 2012-03-22 | 2024-04-28 | Novo Nordisk As | Továbbítószert tartalmazó készítmények és elõállításuk |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| AU2016215350B2 (en) | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
| UA123051C2 (uk) * | 2015-04-08 | 2021-02-10 | Торрент Фармасьютікалз Лімітед | Фармацевтичні склади |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| JP2020527159A (ja) | 2017-07-19 | 2020-09-03 | ノヴォ ノルディスク アー／エス | Ｅｇｆ（ａ）類似体、その製造、製剤および使用 |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| JPWO2024143501A1 (enExample) * | 2022-12-28 | 2024-07-04 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB953626A (en) * | 1961-04-25 | 1964-03-25 | Meito Sangyo Kk | Enteric-coated tablets of dextran sulphate ester and method of preparation thereof |
| US4525339A (en) * | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| JPS5973600A (ja) * | 1982-10-19 | 1984-04-25 | Okayasu Shoten:Kk | 排卵誘発剤 |
| DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
| ZA898331B (en) * | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
| JPH03275633A (ja) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | 生理活性ポリペプチドの吸収促進剤 |
| JPH04149126A (ja) | 1990-10-09 | 1992-05-22 | Mitsubishi Kasei Corp | 経粘膜投与用医薬組成物 |
| IT1245761B (it) * | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
| CA2070061C (en) * | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| CZ282760B6 (cs) * | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| SE501389C2 (sv) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
| RU2068689C1 (ru) * | 1992-09-24 | 1996-11-10 | Товарищество с ограниченной ответственностью "Лекрон" | Способ получения таблеток парацетамола |
| WO1994010983A1 (fr) * | 1992-11-06 | 1994-05-26 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique perorale liberable dans le tube digestif inferieur |
| JPH06192107A (ja) | 1992-12-25 | 1994-07-12 | Sanwa Kagaku Kenkyusho Co Ltd | グリチルリチン経口剤 |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| GB9614235D0 (en) * | 1996-07-06 | 1996-09-04 | Danbiosyst Uk | Composition for enhanced uptake of polar drugs from mucosal surfaces |
-
2000
- 2000-02-22 DE DE60038097T patent/DE60038097T2/de not_active Expired - Lifetime
- 2000-02-22 WO PCT/GB2000/000628 patent/WO2000050012A1/en not_active Ceased
- 2000-02-22 AT AT00905186T patent/ATE386508T1/de not_active IP Right Cessation
- 2000-02-22 ES ES00905186T patent/ES2301477T3/es not_active Expired - Lifetime
- 2000-02-22 JP JP2000600624A patent/JP2002537321A/ja active Pending
- 2000-02-22 AU AU26813/00A patent/AU2681300A/en not_active Abandoned
- 2000-02-22 CA CA2363123A patent/CA2363123C/en not_active Expired - Fee Related
- 2000-02-22 EP EP00905186A patent/EP1154761B1/en not_active Expired - Lifetime
-
2011
- 2011-11-07 JP JP2011243450A patent/JP5412491B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012067115A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| JP2014501784A5 (enExample) | ||
| JP2010505902A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| CN1921840A (zh) | 多层片剂 | |
| JP2016510326A5 (enExample) | ||
| JP2019069981A (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物 | |
| JP2012502015A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2013508289A5 (enExample) | ||
| JPWO2019151405A1 (ja) | 錠剤及びその製造方法 | |
| JP2015521191A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| WO2010001413A3 (en) | Sustained release pharmaceutical compositions comprising quetiapine | |
| JP2015508765A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| JP2013545802A5 (enExample) | ||
| JP2010500284A5 (enExample) | ||
| JP2009502777A5 (enExample) | ||
| WO2005065664A8 (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
| CA2648538A1 (en) | Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles | |
| JP2012506429A5 (enExample) |